Resumen
Oral administration of peptide therapeutics faces challenges because of the distinct environment of the gastrointestinal tract. An oral formulation of semaglutide, a glucagon-like peptide 1 receptor agonist, was approved by the U.S. Food and Drug Administration in 2019 as a peptide therapy for the treatment of type 2 diabetes. Oral semaglutide uses sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) technology to enhance the absorption of semaglutide in the stomach and protect it from degradation by gastric enzymes. This article presents a summary of studies investigating SNAC technology as an absorption enhancer for a number of molecules and, in particular, explores how SNAC, once coformulated with oral semaglutide, facilitates increased absorption and bioavailability. Practical advice and dispensing information for pharmacists is also provided.
Idioma original | English (US) |
---|---|
Páginas (desde-hasta) | 74-86 |
Número de páginas | 13 |
Publicación | Clinical Diabetes |
Volumen | 42 |
N.º | 1 |
DOI | |
Estado | Published - ene 2024 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism